Table 1.
Drug sensitivities
| Drug | HL-60 nM |
HL-60/ara-C10 nM (RR) |
HL-60/CAFdA4 nM (RR) |
HL-60/CAFdA30 nM (RR) |
|---|---|---|---|---|
| Ara-C | 670 | 6900 (10) | > 1000 | > 1000 |
| CAFdA | 60 | 359 (6) | 260 (4) | 1780 (30) |
| Gemcitabine | 3 | 302 (101) | 339 (113) | 2089 (696) |
| Cladribine | 68 | 6154 (91) | 44,700 (657) | 62,100 (913) |
| 50 nM venetoclax + ara-C | 2320 | |||
| 50 nM venetoclax + CAFdA | 120 | 690 |
The IC50 values were calculated by using the XTT assay. RR, relative resistance calculated as the ratio of the IC50 of HL-60/ara-C10, HL-60/CAFdA4, or HL-60/CAFdA30 cells relative to that of HL-60. 50 nM venetoclax + ara-C; Cells were incubated for 72 h with 50 nM venetoclax and with ara-C at different concentrations, 50 nM venetoclax + CAFdA; Cells were incubated for 72 h with 50 nM venetoclax and with CAFdA at different concentrations. Ara-C Cytarabine, CAFdA Clofarabine